



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

22 May 2026  
Committee for Veterinary Medicinal Products

## Summary of opinion<sup>1</sup> (initial authorisation)

---

### Nobivac NXT HCP

Common name: Feline calicivirus, feline viral rhinotracheitis and feline panleucopenia vaccine (live)

On 21 May 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion<sup>2</sup>, recommending the granting of a marketing authorisation for the veterinary medicinal product Nobivac NXT HCP, lyophilisate and solvent for suspension for injection, intended for use in cats. The applicant for this veterinary medicinal product is INTERVET INTERNATIONAL B.V.

Nobivac NXT HCP is an immunological veterinary medicinal product (vaccine) containing feline herpesvirus 1, strain G2620A (live), feline calicivirus, strain F9 (live) and feline panleucopenia virus, strain MW-1 (live) as the active substances.

The benefits of Nobivac NXT HCP are its efficacy for the active immunisation of cats:

- to reduce mortality, clinical signs and virus excretion caused by infection with feline herpesvirus type 1 (FHV) (feline rhinotracheitis virus);
- to reduce the clinical signs and virus excretion caused by infection with feline calicivirus (FCV);
- to prevent mortality, clinical signs, leucopenia and virus excretion caused by infection with feline panleucopenia virus (FPL).

The onset of immunity is 1 week. The duration of immunity is 1 year after primary vaccination and 3 years after re-vaccination for FHV and FCV; and 3 years for FPL.

Nobivac NXT HCP is generally well tolerated at the recommended dose. The most common side effects are injection site swelling and elevated temperature (common).

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

---

<sup>1</sup> Summaries of opinion are published without prejudice to the Commission Decision.

<sup>2</sup> Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.



The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Nobivac NXT HCP and therefore recommends the granting of the marketing authorisation.